Heyu: FGFR4 inhibitor Itepatinib has been granted orphan drug status by the EMA for the treatment of hepatocellular carcinoma

2026-04-10 08:57:51

Heyu-B Announcement, the company’s subsidiary Shanghai Heyu Biomedical Technology Co., Ltd. announced that its independently developed highly selective oral small-molecule FGFR4 inhibitor Irapagratinib(Irpagratinib/ABSK-011) has been granted orphan drug designation (ODD) by the European Medicines Agency (EMA) for the treatment of hepatocellular carcinoma (HCC).

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes